Stock comparison
ImmunityBio
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IBRX
ImmunityBio
Market cap
$7.56B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IBRX | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 75B | IDXX |
| Benjamin Graham | 45D | 80A | IDXX |
| Philip Fisher | 53C | 75B | IDXX |
| Peter Lynch | 52C | 71B | IDXX |
| Joel Greenblatt | 2F | 83C | IDXX |
| Charlie Munger | 53D | 87A | IDXX |
| Terry Smith | 55C | 84A | IDXX |
Side-by-side metrics
| Metric | IBRX | IDXX |
|---|---|---|
| Market cap | $7.56B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | -44.51% | 40.66% |
| Gross margin | 93.79% | 62.05% |
| Net margin | -6.06% | 24.63% |
| Revenue CAGR 5y | 2.32% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IBRX leads on
- EV/EBIT-vs 31.6x+194%
- Debt / Equity-vs 0.7x+154%
- P/E (TTM)-vs 39.0x+123%
- Revenue CAGR 5y2.32%vs 7.56%+97%
IDXX leads on
- ROIC (TTM)40.66%vs -44.51%+191%
- Net margin24.63%vs -6.06%+104%
- Market cap$44.12Bvs $7.56B+83%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.